Lucy Singah has been appointed as Chief Financial Officer (CFO) at Resolution Therapeutics, with Daniel Kennedy being appointed as Chief Business Officer (CBO).
Resolution is a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases.
Amir Hefni, CEO of Resolution Therapeutics, said: “We are delighted to welcome Lucy and Dan to our leadership team. I look forward to working with the strengthened executive team to deliver on our vision to transform patient outcomes by pioneering regenerative macrophage therapy (RMT) in inflammatory and fibrotic diseases.”
Lucy said: “I look forward to collaborating with the team and leveraging my experience to advance the company s financial goals and drive RTX001 through the clinic.”
Lucy has over two decades of experience in corporate and strategic finance in the UK and the US, working with both start-ups and global companies, and she has extensive expertise in financial planning and investor relations.
She was most recently CFO at Echopoint Medical, and prior to that she held various roles at Amazonia Impact Ventures and Axis Spine Technologies. She also spent over a decade at GSK where she held various roles in M&A, Investor Relations, as well as finance leadership in Procurement and Consumer Healthcare.
Daniel also has over two decades of experience, working as a business development executive building partnerships, leading licensing deals and driving strategic transactions in pharma and biotech. Previously he was Vice President, Business Development at Immunocore, and led business development and alliance management at Achillion Pharmaceuticals, before it was acquired by Alexion Pharmaceuticals. Prior to that, Dan held diverse roles at Schering-Plough and GSK.
Daniel said: “I look forward to supporting the Company as it grows, and continues to enrol and treat patients, driving its mission forward.”